News for EHVVF Stock

Ehave Snaps Up AI Headhunter for $10M, Signaling Commitment to AI AIBotics Targets in Q2 2025 Launch for Phill, the world's first AI MASSAGE ROBOT™; Announces Fitness Center Pilot Program in Miami AIBotics Signs Agreement to Develop UI/UX for Phill Robot, Its AI-Powered Massage Robot Mycotopia Therapies Inc. Announces Name Change to AIBiotics, Inc. and Symbol Change to AIBT $40 Million Transaction: AIBiotics Signs Letter of Intent to Acquire Music AI Innovator DigiTrax Entertainment Including Seven Patents and $9 Million Music Catalog Making Ehave Great Again Ehave Provides Progress Update on its HPPD Study with University of Melbourne FDA Grants Ehave Consent to Proceed With Its Clinical Study on Intravenous Ketamine Infusion for Major Depressive Disorder Ehave Shareholder from CEO Ben Kaplan and Corporate Update Ehave, Inc. Announces its KetaDASH Mobile Unit will be Delivered to Miami Beach on June 10, 2022 Ehave, Inc. Announces Psychedelics Precision Medicine Platform For Clinical Research Ehave Announces Mycotopia Therapies Reaches Definitive Agreement on Triangular Merger with Ei.Ventures to Form PSLY.com to List on NASDAQ Ehave Announces MetaHealthU Will Enter The Market With A Focus On HPPD Ehave Continues Expansion Of KetaDASH Mobile Psychedelic Service By Providing Licensed Psychotherapists And Registered Nurses Ehave, Inc. Licensing Partner Vastmindz Seen By Millions Of Viewers On Unicorn Hunter Ehave, Inc. Launches KetaDASH, Its In-Home Ketamine Therapy In The San Francisco And Sacramento Market Ehave, Inc. Expands Its KetaDASH Brand And Begins Producing Revenue With The Purchase Of California Based Rejuv IV Ehave Issues Shareholder Letter and Provides Corporate Update Ehave Plans Stock Distribution; Mycotopia Therapies Plans To Merge With Ei. Ventures 2021 Psychedelic Investor Guide Released Ehave Hires Contract Research Organization To Conduct Ketamine Clinical Trial In Miami, Florida Psychedelic Stock Review Initiates Coverage on Ehave Inc. Ehave Announces Inclusion in the 2021 Psychedelic Investor Guide Ehave Appoints Board-Certified Gastroenterologist And Licensed Physician Dr. Rahul Dixit To Its Medical Advisory Board Ehave Announces Update On Ehave Medical App With The Launch Of Covid Vaccine Passport Going Live Shortly Ehave Files 6-K Disclosing LOI Details For The Acquisition Of Moksha Digital Software Ehave Accelerates Growth With LOI To Acquire India Based Moksha Digital, A Medical Imaging Software Provider Ehave Files 6-K Disclosing Research Project Agreement Ehave acquires License covering G-20 Countries for all Psychedelic use, AI-Powered Telehealth Technology To Capture Physiological Vitals From Vastmindz; Prepares To Run Testing On Dashboard Ehave Partners with Globally Recognized University to Target Hallucinogen Persisting Perception Disorder (HPPD) Hallucinogen Persisting Perception Disorder (HPPD) Research Initiated By Ehave Ehave Releases Additional Information On Partnership With Cutting Edge Data Provider As It Expands Capabilities Ehave Hires Institutional Review Board (IRB) As It Solidifies Partnership With Tristar Wellness Launching Ketamine Clinical Trials In Miami Former member of the National Advisory Council on Drug Abuse (NACDA) and National Institute on Drug Abuse (NIDA) Joins Ehave, Inc; Ehave Appoints Psychopharmacologist, Board-Certified Psychiatrist, And Licensed Physician, Bankole Johnson To Its Medical Advisory Board Ehave, Inc. To Be One Of Four Main Sponsors At The Third Annual Psytech Summit on July 19th and 20th, 2021 Ehave, Inc. Adds Published Child, Adolescent And Adult Psychiatrist To Its Medical Advisory Board Dr. Jeffrey Kamlet Internationally Recognized Expert on Cardiac Safety in Ibogaine Treatment Joins Ehave as Chief Medical Officer Ehave To Release Vaccine Passport As Part Of Its Medical Passport Ehave Expands Dashboard Capabilities to Include Decentralized Trials and Virtual Studies Ehave KetaDASH Subsidiary Commences Data Collection for Potential Patients and Partnering Clinics Ehave, Inc. Announces Engagement of Legal Counsel to Advise on Launch of KetaDASH in Miami Metro Area and across United States; Ehave Creates Path to Revenue Stream Ehave Prepares to Launch Ketamine Clinical Trials Using Brain Scientific’s Brain Mapping Technology Psilocybin Data Study Agreement Reached Between Ehave Inc. and Silo Wellness Using Brain Scientific Mapping Neurocap Ehave CEO Benjamin Kaplan to be Featured on Psychedelic Spotlight Segment of New to the Street Airing on NewsMax on Sunday March 14th at 10:00 AM EST and Fox Business March 15th at 7:30 PM EST Ehave Inc. Files for KetaDash Trademark and to Uplist its Shares to the OTCQB Ehave Inc. Reaches Milestone; Ketamine IV Therapy Provider KetaDASH to Launch Beta in Second Quarter 2021 Ehave Couples KetaDASH with Digital Therapeutics Expertise to Combat Clinical Depression